Shots:

• Samsung Bioepis and Genentech has filed a joint stipulation of dismissal of their BPCIA patent litigation for Ontruzant- a biosimilar of Herceptin
• Under the settlement and license agreement- the companies jointly moved to voluntarily dismiss Bioepis’ appeal of the PTAB’s decisions upholding the patentability of U.S. Patent nos. 6-627-196 & 7-371-379- directed to cancer therapies. The agreement allows Bioepis to commercialize the Ontruzant in the US
• Ontruzant is biosimilar of trastuzumab targeting HER2 receptor- indicated for HER2-overexpressing breast cancer and m-gastric cancer marketed by Merck in the US and has received approval in the US & EU in Nov’2017 & Jan’2019 respectively

Click here to read full press release/ article

 Ref: US District Court | Image: Samsung Bioepis